Department of Clinical Neuroscience, Karolinska Institutet, 171 77 Stockholm, Sweden.
Support Care Cancer. 2010 Nov;18(11):1385-91. doi: 10.1007/s00520-009-0758-4. Epub 2009 Oct 15.
This study aimed to explore the predictive value of systematic inflammatory and metabolic markers in head and neck (H&N) cancer patients during radiotherapy (RT).
Twenty-seven patients were evaluated. The protocol included serial blood tests [highly sensitive C-reactive protein (hsCRP), albumin, insulin-like growth factor 1 (IGF-1), IGF binding protein 1 (IGFBP-1) and ghrelin], measurements of body weight and assessment of oral mucositis.
The mean nadir of weight loss was observed at the end of RT. At the time of diagnosis, mean hsCRP was 5.2 ± 1.0 mg/L. HsCRP significantly increased during RT and decreased during the post-RT period. Mean maximum hsCRP was 35.8 ± 8.5 mg/L, with seven patients reaching >40 mg/L. A numerical decrease of albumin (by 18.2%) and only small changes in IGF-1, IGFBP-1 and ghrelin levels were observed. None of the metabolic parameters was significantly associated with weight loss.
HsCRP increased in response to RT for H&N cancer as a sign of irradiation-induced inflammation. Weight loss was not preceded by changes of the metabolic parameters, indicating that assessment of the blood markers used in this study is of little value. Regular body weight measurement and assessment of oral mucositis are feasible, cheap and important procedures to control the metabolic homeostasis during RT.
本研究旨在探讨系统性炎症和代谢标志物在头颈部(H&N)癌症患者放疗(RT)期间的预测价值。
对 27 例患者进行评估。方案包括连续血液检查[高敏 C 反应蛋白(hsCRP)、白蛋白、胰岛素样生长因子 1(IGF-1)、胰岛素样生长因子结合蛋白 1(IGFBP-1)和 ghrelin]、体重测量和口腔黏膜炎评估。
体重减轻的平均最低点出现在 RT 结束时。在诊断时,hsCRP 的平均水平为 5.2 ± 1.0 mg/L。hsCRP 在 RT 期间显著增加,并在 RT 后期间降低。平均最大 hsCRP 为 35.8 ± 8.5 mg/L,有 7 例患者超过 40 mg/L。白蛋白数值下降(下降 18.2%),IGF-1、IGFBP-1 和 ghrelin 水平仅略有变化。代谢参数均与体重减轻无显著相关性。
hsCRP 作为放疗诱导炎症的标志,在 H&N 癌症的 RT 中增加。体重减轻之前没有代谢参数的变化,这表明本研究中使用的血液标志物的评估几乎没有价值。定期测量体重和评估口腔黏膜炎是控制 RT 期间代谢平衡的可行、经济和重要程序。